At a glance
- IGF-1 LR3 is an engineered 83-amino-acid IGF-1 analogue with an N-terminal extension and an Arg substitution at position 3. It was designed to retain IGF-1-receptor activity while binding less strongly to IGF-binding proteins.
- IGF-1 LR3 is not an approved human medicine. Findings for native IGF-1 or approved mecasermin cannot automatically be assigned to LR3 because sequence, binding-protein affinity, exposure, and product controls differ.
- Compare LR3 with native IGF-1 in the same assay to isolate the effect of reduced IGF-binding-protein interaction.
- Measure receptor activation separately from proliferation or nutrient-response endpoints to avoid overreading a downstream result.
What IGF-1 LR3 is—and what the name does not establish
IGF-1 LR3 is an engineered 83-amino-acid IGF-1 analogue with an N-terminal extension and an Arg substitution at position 3. It was designed to retain IGF-1-receptor activity while binding less strongly to IGF-binding proteins.
Reduced interaction with IGF-binding proteins can leave more analogue available to engage IGF-1 receptors in some experimental systems. In plain language, LR3 changes how the signal is carried and buffered; it is not simply native IGF-1 with a longer clock.
Questions to settle before interpreting a result
A useful IGF-1 LR3 study begins with material identity, a defined model, a relevant comparator, and an endpoint chosen before the result is known. Broad catalogue language cannot replace those controls.
- Compare LR3 with native IGF-1 in the same assay to isolate the effect of reduced IGF-binding-protein interaction.
- Measure receptor activation separately from proliferation or nutrient-response endpoints to avoid overreading a downstream result.
- Confirm cell-line receptor expression and assay media composition because binding proteins can change apparent potency.
How to read the IGF-1 LR3 evidence
These evidence snapshots summarize the most important distinctions in the published record. They do not combine unlike models or turn an experimental signal into a human-use claim.
Analogue design
- Design
- Lower binding-protein affinity changes experimental availability
- Finding
- LR3 was developed as a potent IGF-1 analogue for laboratory and bioprocess applications. Its behaviour depends heavily on IGF-binding proteins, receptor abundance, and the surrounding matrix.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
What not to assume
- Design
- Mecasermin evidence does not transfer to LR3
- Finding
- Approved recombinant human IGF-1 is a different molecule and drug product. Clinical dosing, safety, and outcomes for mecasermin are not evidence for long-R3 IGF-1 material.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
Assay context
- Design
- Media composition can reverse an apparent comparison
- Finding
- Serum and IGF-binding proteins change how much LR3 or native IGF-1 is freely available. Potency rankings should stay attached to the exact assay conditions.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
What the evidence does not establish
IGF-1 LR3 is not an approved human medicine. Findings for native IGF-1 or approved mecasermin cannot automatically be assigned to LR3 because sequence, binding-protein affinity, exposure, and product controls differ.
Mechanism, cell, animal, observational, and controlled human evidence answer different questions. A positive result at one level cannot be silently promoted to another, and evidence for a sponsor’s defined product does not establish equivalence for an independently sourced research material.
Keep the publication and the vial separate
A published paper identifies its own sequence or chemical identity, formulation, manufacturing context, analytical controls, exposure, and test system. Matching a familiar name on a label is not enough to show that a catalogue vial is the same study material.
For practical research planning, verify the lot-specific identity and documentation, then write the model, comparator, endpoint, and stopping criteria before testing. This guide does not provide preparation, dosing, injection, or human-use instructions.
Sources
Links lead to the paper, official registry, regulator page, or product label used for this guide. Registry records describe protocols and status; they are not treated as positive results.
- Long R3 insulin-like growth factor-I infusion and IGF-binding-protein-dependent responsesPubMed-indexed primary study · 1995
Primary animal study comparing LR3IGF-I with native IGFs. Its binding-protein context and model must remain attached to the reported response.
- Think twice before injecting peptides bought online: unauthorized products can seriously harm youHealth Canada · 2026
Official Canadian advisory explaining that a research-use label does not establish authorization, safety, efficacy, or product quality for human use.
Vote for IGF-1 LR3
This compound is not currently stocked. Add it to your five-choice catalogue ballot.